Tandem Capital Management Corp ADV Sells 280 Shares of Danaher Co. (NYSE:DHR)

Tandem Capital Management Corp ADV reduced its holdings in Danaher Co. (NYSE:DHR) by 1.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 15,237 shares of the conglomerate’s stock after selling 280 shares during the quarter. Danaher comprises 2.2% of Tandem Capital Management Corp ADV’s holdings, making the stock its 11th largest holding. Tandem Capital Management Corp ADV’s holdings in Danaher were worth $3,525,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in DHR. BKM Wealth Management LLC bought a new stake in Danaher in the fourth quarter worth approximately $27,000. Wetzel Investment Advisors Inc. bought a new stake in Danaher in the fourth quarter worth approximately $29,000. OFI Invest Asset Management acquired a new stake in Danaher in the third quarter valued at approximately $30,000. Rakuten Securities Inc. acquired a new stake in Danaher in the fourth quarter valued at approximately $36,000. Finally, GHP Investment Advisors Inc. grew its stake in Danaher by 540.0% in the third quarter. GHP Investment Advisors Inc. now owns 160 shares of the conglomerate’s stock valued at $40,000 after acquiring an additional 135 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

DHR stock traded down $4.59 during midday trading on Thursday, hitting $245.82. The company’s stock had a trading volume of 2,943,521 shares, compared to its average volume of 2,786,286. The stock’s 50-day moving average price is $248.94 and its 200 day moving average price is $230.88. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00. The stock has a market cap of $182.04 billion, a price-to-earnings ratio of 41.66, a PEG ratio of 4.24 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.48% and a net margin of 16.78%. The business’s revenue was down 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.36 earnings per share. On average, equities analysts forecast that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a $0.27 dividend. The ex-dividend date is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s payout ratio is presently 18.31%.

Insider Buying and Selling at Danaher

In other Danaher news, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the sale, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the sale, the director now directly owns 19,726 shares in the company, valued at approximately $4,898,360.32. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 4,000 shares of the business’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the sale, the senior vice president now owns 29,830 shares in the company, valued at $7,457,798.30. The disclosure for this sale can be found here. Insiders have sold a total of 84,132 shares of company stock worth $21,022,795 over the last ninety days. 11.10% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on DHR shares. Bank of America raised their price objective on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday. HSBC raised Danaher from a “hold” rating to a “buy” rating and raised their price objective for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Citigroup raised their price objective on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday. Robert W. Baird raised their price objective on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, KeyCorp lifted their target price on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Six research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average price target of $270.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.